These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 36725417)

  • 1. Gene editing for dyslipidemias: New tools to "cut" lipids.
    Stankov S; Cuchel M
    Atherosclerosis; 2023 Mar; 368():14-24. PubMed ID: 36725417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing.
    Chadwick AC; Musunuru K
    Curr Atheroscler Rep; 2017 Jul; 19(7):32. PubMed ID: 28550381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing.
    Srivastava RAK
    Nutr Metab Cardiovasc Dis; 2023 Dec; 33(12):2317-2325. PubMed ID: 37805309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Versatile Nonviral Delivery System for Multiplex Gene-Editing in the Liver.
    Gong J; Wang HX; Lao YH; Hu H; Vatan N; Guo J; Ho TC; Huang D; Li M; Shao D; Leong KW
    Adv Mater; 2020 Nov; 32(46):e2003537. PubMed ID: 33053221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
    Kim K; Ginsberg HN; Choi SH
    Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases.
    Landmesser U; Poller W; Tsimikas S; Most P; Paneni F; Lüscher TF
    Eur Heart J; 2020 Oct; 41(40):3884-3899. PubMed ID: 32350510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Editing for the Treatment of Hypercholesterolemia.
    Hoekstra M; Van Eck M
    Curr Atheroscler Rep; 2024 May; 26(5):139-146. PubMed ID: 38498115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of New Genome Editing Tools for the Treatment of Hyperlipidemia.
    Preta G
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Trends in Dyslipidemia Treatment.
    Jang AY; Lim S; Jo SH; Han SH; Koh KK
    Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
    Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
    Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia.
    Wiggins BS
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
    Chadwick AC; Musunuru K
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting
    Lee RG; Mazzola AM; Braun MC; Platt C; Vafai SB; Kathiresan S; Rohde E; Bellinger AM; Khera AV
    Circulation; 2023 Jan; 147(3):242-253. PubMed ID: 36314243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the management and implementation of care for familial hypercholesterolaemia.
    Lan NSR; Bajaj A; Watts GF; Cuchel M
    Pharmacol Res; 2023 Aug; 194():106857. PubMed ID: 37460004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
    Chadwick AC; Wang X; Musunuru K
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy.
    Li ZF; Wu NQ
    Front Genet; 2022; 13():911429. PubMed ID: 35754818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Bajaj A; Cuchel M
    Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.